Testosterone replacement therapy for older men

Journal of Andrology

Volumn 27, Issue 2, 2006, Pages 126-132

  Wald, Moshe ^a   Meacham, Randall B ^b   Ross, Lawrence S ^c   Niederberger, Craig S ^c  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE; TESTOSTERONE PROPIONATE; TESTOSTERONE UNDECANOATE;

ACNE; AGING; APPLICATION SITE ERYTHEMA; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; FLUID RETENTION; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; LEG EDEMA; LIVER TOXICITY; MALE; PATIENT MONITORING; POLYCYTHEMIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN INDURATION; SKIN IRRITATION; TESTOSTERONE BLOOD LEVEL;

AGED; AGING; DRUG MONITORING; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; MIDDLE AGED; SKIN; TESTOSTERONE;

EID: 33644501498     PISSN: 01963635     EISSN: None     Source Type: Journal    
DOI: 10.2164/jandrol.05036     Document Type: Review

References (70)

1. AACE Hypogonadism Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients-2002 update. Endocr Pract. 2002;8:439-456.
2. Anonymous. Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res. 2002;17:716-724.
3. Arver S, Dobs AS, Meikle AW, Caramelli KE, Rajaram L, Sanders SW, Mazer NA. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. Clin Endocrinol Oxford. 1997;47:727-737.
4. Baker HW, Burger HG, de Kretser DM, Hudson B, O'Connor S, Wang C, Mirovics A, Court J, Dunlop M, Rennie GC. Changes in the pituitary-testicular system with age. Clin Endocrinol Oxford. 1976;5:349-372.
5. Basaria S, Dobs AS. Hypogonadism and androgen replacement therapy in elderly men. Am J Med. 2001;110:563-572.
6. Bhasin S, Bagatell CJ, Bremner WJ, Plymate SR, Tenover JL, Korenman SG, Nieschlag E. Issues in testosterone replacement in older men. J Clin Endocrinol Metab. 1998;83:3435-3448.
7. Bhasin S, Bremner WJ. Emerging issues in androgen replacement therapy. J Clin Endocrinol Metab. 1997;82:3-8.
8. Bhasin S, Gabelnick HL, Spieler JM, Swerdloff RS, Wang C, Kelly C, eds. Pharmacology, Biology and Clinical Applications of Androgen. New York, NY: Wiley Liss; 1996.
9. Bhasin S, Swerdloff RS, Steiner B, Peterson MA, Meridores T, Galmirini M, Pandian MR, Goldberg R, Berman N. A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men. J Clin Endocrinol Metab. 1992;74:75-83.
10. Blum J, Harris RH. Diagnosis and treatment of hypogonadism with emphasis on erectile dysfunction and osteoporosis. Prim Care Case Rev. 2003;6:97-109.
11. Bouloux P. Testim 1% testosterone gel for the treatment of male hypogonadism. Clin Ther. 2005;27:286-298.
12. Bremner WJ, Prinz PN. A loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab. 1983;56:1278-1281.
13. Brocks DR, Meikle AW, Boike SC, Mazer NA, Zariffa N, Audet PR, Jorkasky DK. Pharmacokinetics of testosterone in hypogonadal men after transdermal delivery: influence of dose. J Clin Pharmacol. 1996;36:732-739.
14. Cunningham GR, Cordero E, Thornby JI. Testosterone replacement with transdermal therapeutic systems. JAMA. 1989:261:2525-2530.
15. Davidson JM, Chen JJ, Crapo L, Gray GD, Greenleaf WJ, Catania JA. Hormonal changes and sexual function in aging men. J Clin Endocrinol Metab. 1983;57:71-77.
16. Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab. 1999;84:3469-3478.
17. Ferrini RL, Barrett-Connor E. Sex hormones and age: a cross-sectional study of testosterone and estradiol and their bioavailable fractions in community-dwelling men. Am J Epidemiol. 1998;147:750-754.
18. Findlay JC, Place V, Snyder PJ. Treatment of primary hypogonadism in men by the transdermal administration of testosterone. J Clin Endocrinol Metab. 1989;68:369-373.
19. Gerstenbluth RE, Maniam PN, Corty EW, Seftel AD. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement. J Androl. 2002;23:922-926.
20. Gooren LJ, Bunck MC. Androgen replacement therapy: present and future. Drugs. 2004;64:1861-1891.
21. Gray A, Berlin JA, McKinlay JB, Longcope C. An examination of research design effects on the association of testosterone and male aging: results of a meta-analysis. J Clin Epidemiol. 1991;44:671-684.
22. Gruenewald DA, Matsumoto AM. Testosterone supplementation therapy for older men: potential benefits and risks. J Am Geriatr Soc. 2003;51:101-115.
23. Handelsman DJ, Conway AJ, Boylan LM. Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J Clin Endocrinol Metab. 1990;71:216-222.
24. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab. 2001;86:724-731.
25. Hughes VA, Frontera WR, Roubenoff R, Evans WJ, Singh MA. Longitudinal changes in body composition in older men and women: role of body weight change and physical activity. Am J Clin Nutr. 2002;76:473-481.
26. Jockenhovel F. Testosterone supplementation: what and how to give. Aging Male. 2003;6:200-206.
27. Jockenhovel F. Testosterone therapy-what, when and to whom? Aging Male. 2004;7:319-324.
28. Jordan WP. Allergy and topical irritation associated with transdermal testosterone administration: a comparison of scrotal and non-scrotal transdermal systems. Am J Contact Dermat. 1997;8:108-113.
29. Jordan WP, Atkinson LE, Lai C. Comparison of the skin irritation potential of two testosterone transdermal systems: an investigational system and a marketed product. Clin Ther. 1998;20:80-87.
30. Kaufman JM. The effect of androgen supplementation therapy on the prostate. Aging Male. 2003;6:166-174.
31. Kohn FM, Schill WB. A new oral testosterone undecanoate formulation. World J Urol. 2003;21:311-315.
32. Korbonits M, Kipnes M, Grossman AB. Striant SR: a novel, effective and convenient testosterone therapy for male hypogonadism. Int J Clin Pract. 2004;58:1073-1080.
33. Korenman SG. A pragmatic approach to androgen replacement in older men: risks vs. benefits. J Clin Endocrinol Metab. 1998;83:3441-3443.
34. Liu PY, Swerdloff RS, Veldhuis JD. The rationale, efficacy and safety of androgen therapy in older men: future research and current practice recommendations. J Clin Endocrinol Metab. 2004;89:4789-4796.
35. Matsumoto AM, Bremner WJ. Serum testosterone assays-accuracy matters. J Clin Endrocrinol Metab. 2004;89:520-524.
36. McClellan KJ, Goa KL. Transdermal testosterone. Drugs. 1998;55:253-258.
37. Meikle AW, Arver S, Dobs AS, Adolfsson J, Sanders SW, Middleton RG, Stephenson RA, Hoover DR, Rajaram L, Mazer NA. Prostate size in hypogonadal men treated with nonscrotal permeation-enhanced testosterone transdermal system. Urology. 1997;49:191-196.
38. Meikle AW, Arver S, Dobs AS, Sanders SW, Rajaram L, Mazer NA. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site-a clinical research center study. J Clin Endocrinol Metab. 1996;81:1832-1840.
39. Meikle AW, Mazer NA, Moellmer JF, Stringham JD, Tolman KG, Sanders SW, Odell WD. Enhanced transdermal delivery of testosterone across the nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J Clin Endocrinol Metab. 1992;74:623-628.
40. Morley JE, Kaiser FE, Perry HM III, Patrick P, Morley PM, Stauber PM, Vellas B, Baumgartner RN, Garry PJ. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism. 1997;46:410-413.
41. Nguyen TV, Eisman JA, Kelly PJ, Sambrook PN. Risk factors for osteoporotic fractures in elderly men. Am J Epidemiol. 1996;144:255-263.
42. Nieschlag E, Bals-Pratsch M. Transdermal testosterone. Lancet. 1989;1:1146-1147.
43. Nieschlag E, Behre HM, eds. Testosterone: Action, Deficiency, Substitution. 2nd ed. New York, NY: Springer; 1998.
44. Partsch CJ, Weinbauer GF, Fang R, Nieschlag E. Injectable testosterone undecanoate has more favourable pharmacokinetics and pharmacodynamics than testosterone enanthate. Eur J Endocrinol. 1995;132:514-519.
45. Pirke KM, Doerr P. Age-related changes in free plasma testosterone, dihydrotestosterone and oestradiol. Ada Endocrinol Copenh. 1975;80:171-178.
46. Plymate SR. Which testosterone assay should be used in older men? J Clin Endocrinol Metab. 1998;83:3436-3438.
47. Purifoy FE, Koopmans LH, Mayes DM. Age differences in serum androgen levels in normal adult males. Hum Biol. 1981;53:499-511.
48. Rantanen T, Masaki K, Foley D, Izmirlian G, White L, Guralnik JM. Grip strength changes over 27 yr in Japanese-American men. J Appl Physiol 1998;85:2047-2053.
49. Rhoden EL, Morgentaler A. Risks of testosterone replacement therapy and recommendations for monitoring. N Engl J Med. 2004;350:482-492.
50. Rubens R, Dhont M, Vermeulen A. Further studies on Leydig cell function in old age. J Clin Endocrinol Metab. 1974;39:40-45.
51. Salehian B, Wang C, Alexander G, Davidson T, McDonald V, Berman N, Dudley RE, Ziel F, Swerdloff RS. Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate-a clinical research center study. J Clin Endocrinol Metab. 1995;80:3567-3575.
52. Santavirta S, Konttinen YT, Heliovaara M, Knekt P, Luthje P, Aromaa A. Determinants of osteoporotic thoracic vertebral fracture. Screening of 57,000 Finnish women and men. Acta Orthop Scand. 1992;63:198-202.
53. Sokol RZ, Palacios A, Campfield LA, Saul C, Swerdloff RS. Comparison of kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertil Steril. 1982;37:425-430.
54. Swerdloff RS, Bhasin S, Blackman MR, et al. Summary of the concensus session from the 1st Annual Andropause Concensus 2000 Meeting, 28-30 April 2000, Beverly Hills, CA. Bethesda, Md: Endocrine Society Press; 2000:1-6.
55. Swerdloff RS, Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Longstreth J, Berman N. Long-term pharmacokinetics of transdermal testosterone in hypogonadal men. J Clin Endocrinol Metab. 2000;85:4500-4510.
56. Tenover JL. Testosterone and the aging male. J Androl. 1997;18:103-106.
57. Tenover JL. Testosterone replacement therapy in older adult men. Int J Androl. 1999;22:300-306.
58. Tenover JS, Matsumoto AM, Plymate SR, Bremner WJ. The effects of aging in normal men on bioavailable testosterone and luteinizing hormone secretion: response to clomiphene citrate. J Clin Endocrinol Metab. 1987;65:1118-1126.
59. Vermeulen A. Androgen replacement therapy in the aging male-a critical evaluation. J Clin Endocrinol Metab. 2001;86:2380-2390.
60. Vermeulen A, Rubens R, Verdonck L. Testosterone secretion and metabolism in male senescence. J Clin Endocrinol Metab. 1972;34:730-735.
61. Wang C, Berman N, Longstreth JA, Chuapoco B, Hull L, Steiner B, Faulkner S, Dudley RE, Swerdloff RS. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study. J Clin Endocrinol Metab. 2000;85:964-969.
62. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Berman N, Hull L, Swerdloff RS. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2004a;89:2085-2098.
63. Wang C, Swerdloff RS. Androgen replacement therapy. Ann Med. 1997;29:365-370.
64. Wang C, Swerdloff RS. Androgen replacement therapy, risks and benefits. In: Wang C, ed. Male Reproductive Function. Boston, Mass: Kluwer; 1999:157-172.
65. Wang C, Swerdloff R, Kipnes M, Matsumoto AM, Dobs AS, Cunningham G, Katznelson L, Weber TJ, Friedman TC, Snyder P, Levine HL. New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. J Clin Endocrinol Metab. 2004b;89:3821-3829.
66. Wilson DE, Meikle AW, Boike SC, Hairless AJ, Etheredge RC, Jorkasky DK. Bioequivalence assessment of a single 5 mg/day testosterone transdermal system versus two 2.5 mg/day systems in hypogonadal men. J Clin Pharmacol. 1998;38:54-59.
67. Wittert GA, Chapman IM, Haren MT, Mackintosh S, Coates P, Morley JE. Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol A Biol Sci Med Sci. 2003;58:618-625.
68. Yu Z, Gupta SK, Hwang SS, Cook DM, Duckett MJ, Atkinson LE. Transdermal testosterone administration in hypogonadal men: comparison of pharmacokinetics at different sites of application and at the first and fifth days of application. J Clin Pharmacol. 1997a;37:1129-1138.
69. Yu Z, Gupta SK, Hwang SS, Kipnes MS, Mooradian AD, Snyder PJ, Atkinson LE. Testosterone pharmacokinetics after application of an investigational transdermal system in hypogonadal men. J Clin Pharmacol. 1997b;37:1139-1145.
70. Zmuda JM, Cauley JA, Kriska A, Glynn NW, Gutai JP, Kuller LH. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13-year follow-up of former Multiple Risk Factor Intervention Trial participants. Am J Epidemiol. 1997;146:609-617.